Henningfield JE, Coe MA, Griffiths RR, Belouin SJ, Berger A, Coker AR, Comer SD, Heal DJ, Hendricks PS, Nichols CD, Sapienza F, Vocci FJ, Zia FZ. Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling. Neuropharmacol, 2022; 218: 109220. doi.org/10.1016/j.neuropharm.2022.109220. Read more...
Gray RA, Heal DJ, Maguire DR, Gerak LR, Javors MA, Smith S, France CP. Preclinical assessment of the abuse potential of purified botanical cannabidiol: self-administration, drug discrimination, and physical dependence. J Pharmacol Exp Ther, 2022 Jul; 382(1): 54-65. doi: 10.1124/jpet.121.000988. Epub 2022 Apr 30. Read more...
Syan C, Bowen C, Heal DJ, Froger-Colléaux C, Beardsley PM, Dedic N, Hopkins SC, Campbell U, Koblan KS. Ulotaront, a novel TAAR1 agonist with 5-HT1A agonist activity, lacks abuse liability and attenuates cocaine cue-induced relapse in rats. Drug Alcohol Depend, 2022 Feb 1; 231: 109261. doi: 10.1016/j.drugalcdep.2021.109261. Epub 2021 Dec 31. Read more...
Palandri J, Smith SL, Heal DJ, Wonnacott S, Baily CP. Contrasting effects of the α7 nicotinic receptor antagonist methyllycaconitine in different rat models of heroin reinstatement. J Psychopharmacol, 2021 Oct; 35(10): 1204-1215. doi: 10.1177/0269881121991570. Epub 2021 Mar 10. Read more...
Smith SL, Dean RL, Todtenkopf MS, Heal DJ. Investigation of the reinforcing potential of samidorphan and naltrexone by fixed and progressive ratio intravenous self-administration testing in heroin-maintained rats. J Psychopharmacol, 2019 Mar; 33(3): 383-391. doi: 10.1177/0269881118822111. Epub 2019 Jan 24. Read more...
Wright VL, Georgiou P, Bailey A, Heal DJ, Bailey CP, Wonnacott S. Inhibition of α7 nicotinic receptors in the ventral hippocampus selectively attenuates reinstatement of morphine-conditioned place preference and associated changes in AMPA receptor binding. Addict Biol, 2019; 24: 590-603. Read more...
Heal DJ, Henningfield J, Frenguelli BG, Nutt DJ, Smith SL. Psychedelics - Re-opening the doors of perception. Neuropharmacol, 2018; 142: 1-6.
Heal DJ, Gosden J, Smith SL. Evaluating the abuse potential of psychedelic drugs as part of the safety pharmacology assessment for medical use in humans. Neuropharmacol, 2018; 142: 89-115. Read more...
Calderon S, Giarola A, Heal D. Regulatory Framework and Guidance to the Evaluation of the Abuse Liability of Drugs in the United States and Europe. In: Markgraf CG, Hudzik TJ, Compton DR (Eds). Nonclinical Assessment of Abuse Potential for New Pharmaceuticals. Academic Press, pp. 245–268, 2015.
Heal DJ, Smith SL, Henningfield JE. CNS stimulants. Neuropharmacol, 2014; 87: 1-3.
Heal DJ, Gosden J, Smith SL. Dopamine reuptake transporter (DAT) "inverse agonism" - A novel hypothesis to explain the enigmatic pharmacology of cocaine. Neuropharmacol, 2014; 87: 19-40. Read more...
Heal DJ, Smith SL, Gosden J, Nutt DJ. Amphetamine, past and present – A pharmacological and clinical perspective. J Psychopharmacol, 2013; 27: 479-496. Read more...
Heal DJ, Buckley NW, Gosden J, Slater N, France CP, Hackett D. A preclinical evaluation of the discriminative and reinforcing properties of lisdexamfetamine in comparison to D-amfetamine, methylphenidate and modafinil. Neuropharmacol, 2013; 73: 348-358. Read more...
Rowley HL, Kulkarni R, Gosden J, Brammer R, Hackett D, Heal DJ. Lisdexamfetamine and immediate-release D-amfetamine - differences in pharmacokinetic/pharmacodynamic relationships revealed by striatal microdialysis in freely-moving rats with simultaneous determination of plasma drug concentrations and locomotor activity. Neuropharmacol, 2012; 63: 1064-1074. Read more...
Kennett A, Heal DJ, Wonnacott S. Pharmacological differences between rat frontal cortex and hippocampus in the nicotinic modulation of noradrenaline release implicate distinct receptor subtypes. Nicotine Tob Res, 2012; 14: 1339-1345. Read more...
Freeman KB, Heal DJ, McCreary AC, Woolverton WL. Assessment of ropinirole as a reinforcer in rhesus monkeys. Drug Alcohol Depend, 2012; 125: 173-177.
Sidhpura N, Redfern P, Rowley H, Heal D, Wonnacott S. Comparison of the effects of bupropion and nicotine on locomotor activation and dopamine release in vivo. Biochem Pharmacol, 2007; 74: 1292-1298. Read more...